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A quantitative structure activity relationship (QSAR) study was performed on the fluroquinolones known to have anti-tuberculosis 
activity. The 3D-QSAR models were generated using stepwise variable selection of the four methods - multiple regression (MR), 
partial least square regression (PLSR), principal component regression (PCR) and artificial neural networks (kNN-MFA). The 
statistical result showed a significant correlation coefficient q2 (90%) for MR model and an external test set of (pred_r2) -1.7535, 
though the external predictivity showed to improve using kNN-MFA method with pred_r2 of -0.4644. Contour maps showed that 
steric effects dominantly determine the binding affinities. The QSAR models may lead to a better understanding of the structural 
requirements of anti-tuberculosis compounds and also help in the design of novel molecules. 
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Tuberculosis is a common and often a deadly infectious disease 
caused by Mycobacterium tuberculosis H37Rv claiming more lives 
each year than any other bacterial disease. Despite the 
availability of effective direct observed treatment or short-
course chemotherapy (DOTS) and Bacille Calmette-Guerin 
(BCG) vaccine, the tubercle bacillus continues to claim more 
lives than any single effective agent [1]. Due to the extensive 
period of treatment, patients fail to complete the therapy 
leading to the emergence of drug resistance-multidrug 
resistance (MDR) and extensive drug resistance (XDR) in 
tuberculosis. The widespread emergences of drug resistant 
strains together with human immunodeficiency virus (HIV) 
have been witnessed in the increased incidence of tuberculosis 
in both developing and industrialized countries [1]. It has been 
estimated that tuberculosis accounts for around 32 per cent 
deaths in HIV infected individuals [2]. The recent rise in 
tuberculosis cases and especially the increase in number of drug 
resistant mycobacteria strains indicate an urgent need to 
develop new anti-tuberculosis drugs. The quinolones are a 
group of a wide range of synthetic antibiotics derived from 
nalidixic acid. They are characterized by an atom of fluorine 
and an aryl substituent at position 6 and 7 respectively and are 
known to exhibit an antibacterial spectrum including 
Mycobacterium tuberculosis [3]. When using fluroquinolones for 
the treatment of tuberculosis, individual susceptibility, 
pharmacokinetic and toxicity profiles should be carefully 
considered [4]. 
 
The present study is aimed to understand the structure activity 
of the available fluroquinolones and to obtain the predictive 
quantitative structure activity relationship (QSAR) models. A 
stochastic search method such as multiple regressions (MR), 
partial least square regression (PLSR), principal component 
regression (PCR) and an artificial neural network (kNN-MFA) 
[5-9] was developed to provide an insight to the various 
interactive fields of different compounds in concord with the in 
vitro experimental data. Different QSAR approaches have been BIOINFORMATION  open access 
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developed through the years and the rapid increase in three-
dimensional (3D) structure of the biological molecules have led 
to the development of 3D structural descriptors and associated 
3D QSAR methods [10]. The generated models could provide a 
valuable reference in the design of pharmaceuticals with 
improved anti-tubercular activity. 
 
Methodology:  
3D QSAR study of the molecules was performed using VLife 
Molecular Design Suite [11] allowing users to choose the probe, 
grid size, grid interval and other parameters for generation of 
descriptors. 
 
Dataset for 3D QSAR 
Depending on the antibacterial activity and the toxicity to 
humans, anti-tuberculosis drugs are classified into first-line 
drugs as the first choice of treatment in new cases of TB and 
second-line drugs for treatment of patients with M. tuberculosis 
resistant to the first-line drugs and these were considered for 
QSAR. The chemical structures of the molecules were retrieved 
from Pubchem compound database at National Center for 
Biotechnology Information (NCBI) [12]. Activity of the drugs 
was taken from reported work given as MIC values [3, 13]. The 
biological activity (IC50) of the molecules were converted to 
their corresponding pIC50 values Table 1 (see supplementary 
material)  and used as dependent variables in the QSAR 
calculations. The molecules were first optimized to their lowest 
energy state using Merck molecular force field (MMFF) method 
[14] with RMS gradient of 0.001 and alignment was done based 
on a template structure. Alignment of the molecules is one of 
the most important factors in obtaining a reliable model. 
 
Calculation of descriptors and data selection  
The aligned molecules were selected for calculation of the 
descriptors after inserting the biological activity as a dependent 
variable. The field descriptors were calculated with cutoffs of 
10kcal/mol for electrostatic and 30kcal/mol for steric at lattice 
points of the grid using a methyl probe of charge +1. A grid was 
generated with grid interval of 2Å in a 3-dimensional lattice 
around the aligned molecules. The dielectric constant was set to 
1.0 and with suitable charge type [11]. Invariable columns not 
contributing to the QSAR were removed. Biological activity was 
selected as a dependent variable and the descriptors generated 
were selected as indepenedent variables. The training and test 
sets were generated using the sphere exclusion method which 
allows construction of the training set covering all the 
descriptor space areas occupied by representative points [15] 
and the dissimilarity values was set to 15.75. The unicolumn 
statistics of the training and test sets was calculated for the 
correct selection of the training and test sets.  
 
Variable selection and model building  
The aligned molecules were subjected to regression analysis 
using multiple regressions (MR) which estimates the value of 
regression coefficient by applying least square curve fitting 
model, partial least square regression (PLSR), an extension of 
MR model without imposing any restrictions. Principal 
component regression (PCR) selects a new set of axis such that 
for the first set of axis it reflects most of the variations within 
the data and k-nearest-neighbor (kNN) molecular field analysis 
(MFA) as building methods. The models were developed using 
stepwise (forward-backward) variable selection method with 
cross-correlation limit set to 0.5 with the term selection criteria 
as r2 for MR, PLSR and PCR and q2 for kNN-MFA. F-test ‘in’ 
was set 4.0 and f-test ‘out’ was set to 3.99 and scaling to 
autoscaling. KNN-MFA parameter setting was within the range 
of 2-5 and the distance-based weighted average prediction 
method was selected for the study. 
 
Discussion: 
The fluroquinolones which show activity against tuberculosis 
taken for study were optimized to their lowest energy state and 
aligned with a template. Of the 33 fluroquinolones considered, 
14 quinolones did not align with the template and therefore 
were not considered for further study. The fluroquinolones 
aligned to the template (Figure 1) were considered for QSAR 
studies. The training and test set selected by sphere exclusion 
method show that the maximum of the test is less than 
maximum of training and minimum of test is greater than 
minimum of training set Table 2 (see supplementary material) 
indicating that the test is interpolative and derived within the 
min-max range of the training set. The mean of the training is 
higher than the mean of test set showing the presence of 
relatively less active molecules compared to the active ones. 
Also, a relatively higher standard deviation in the training set 
indicates that the training set has a widely distributed activity 
as compared to the test set. The 3D QSAR study of the 
fluroquinolones through MR, PLSR, PCR and kNN-MFA 
analysis using VLifeMDS resulted in the following statistical 
model. The statistical model (Model 1) shows a significant 
activity-descriptors relationship accuracy of 95% (r2= 0.9507) 
representing part of variation in the observed data, an activity 
prediction accuracy of 90% (q2= 0.9097) and a decrease in the 




Figure 1: 3D-alignment of the fluroquinolones based on a 
template structure 
 
Model 1 (MR) 
Log p (IC50) = -17.2439*S_1379 – 0.0210*S_588 +14.7252*S_498 – 
0.6401 
n = 13, Degree of freedom = 9, r2 = 0.9507, q2 = 0.9097, F test = 
57.8086, r2 se = 0.1606, q2 se = 0.2172, pred_r2 = -1.7535, 
pred_r2se = 0.6996  BIOINFORMATION  open access 
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The same data was subjected to PLSR method which results in a 
correlation of 95% (r2= 0.9498) and a low prediction accuracy of 
89% (q2= 0.8976) with a decrease in external predictivity 
(pred_r2=-1.7493). S_1379 and S_558 contribute negatively and 
S_498 contributes positively in both MR and PLSR, thus groups 
should be altered around the points to reduce the interactions. 
 
Model 2 (PLSR) 
Log p (IC50) = -16.7654*S_1379 -0.02195*S_558 + 15.61775*S_498; 
Optimum Components = 2, n = 13, Degree of freedom = 10, r2 = 
0.9498, q2 = 0.8976, F test = 94.6739, r2 se = 0.1536, q2 se = 
0.2194, pred_r2 = -1.7493, pred_r2se = 0.6991 
 
To improve the external predictivity of the model, PCR analysis 
was performed with the same set of data resulting in a 
regression coefficient of 97% (r2=0.9700) with an internal 
predictive accuracy of 86% (q2=0.8636) and a decrease of the 
external predictivity (pred_r2 = -1.8522). S_1379 contributes 
negatively and S_560 and S_618 contribute positively to the 
activity. 
 
Model 3 (PCR) 
Logp (IC50) = -13.1600*S_1379 + 12.7354*S_560 + 6.8894*S_618 + 
0.1260; Optimum Components = 2, n = 13, Degree of freedom = 
10, r2 = 0.9700, q2 = 0.8636, F test = 161.7857, r2 se = 0.1188, q2 
se = 0.2533, pred_r2 = -1.8522, pred_r2se = 0.7120  
 
To further improve the external predictivity of the model, kNN-
MFA analysis of the fluroquinolone groups was performed and 
found to be statistically significant in terms of the external 
predictivity of the test with an internal predictivity of 33% (q2= 
0.3290) measuring the reliability of the prediction to be reliable 
and accurate. The pred_r2 obtained for the test set showed a 
decreased but an improved result of the external predictivity of 
pred_r2=-0.4644. Descriptor S_242 contributing to the activity 
negatively indicates that a negative steric potential would 
favour for the increase activity. 
 
Model 4 (kNN-MFA) 
S_242 (-0.0019 to -0.0016), k Nearest Neighbour= 2, n = 13, 
Degree of freedom = 11, q2 = 0.3290, q2_se = 0.5129, Predr2 = -
0.4644, pred_r2se = 0.5102.  
 
 
Figure 2: Contribution plot of interaction to the MR model 
 
Figure 3: Fitness plot of observed vs predicted activities of the 
MR model 
 
The PCR contour plots (Figure 2) showed the relative position 
and range of the corresponding important steric field in the 
model. The experimental and predicted activity of the model is 
shown as the fitness plot (Figure 3) for PCR. The nearness of the 
predicted to the observed activity is reported in Table 3 (see 
supplementary material). The models obtained for QSAR 
showed that the steric interactions play an important role in 
determining the biological activity of the models (Figure 4). The 
negative range in the steric descriptors indicates that the 
negative steric potential is favourable for the increase in the 




Figure 4: Contribution chart of statistically significant models 
 
Conclusion: 
The present study was aimed at deriving the predictive 3D 
QSAR models capable of revealing the structural requirement 
for anti-tuberculosis inhibitors. Comparison of the different 
statistical parameters of the four models suggests model 1 for 
further consideration having a better internal predictivity of q2= 
0.9097 and an external test of pred_r2= -1.7535. Model 4 (kNN-
MFA) though has a bad internal predictivity of q2 = 0.3290, the 
external predictivity (pred_ r2=-0.4644) of the test is better as 
compared to the other models. The models show that steric 
effects dominantly determine the binding affinities indicating 
both a positive and a negative contribution suggesting a more 
bulky group is favored in the region where there is positive 
contribution and a less bulky group is favourable in the region 
with negative contribution. Modification of these regions will 
lead to better and improved compounds for the treatment of BIOINFORMATION  open access 
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tuberculosis. The MR and kNN-MFA models developed show 
potential predictive ability as determined by testing the external 
test set. The QSAR models may lead to a better understanding 
of the structural requirements of anti-tuberculosis compounds 
and also help in designing of novel molecules. 
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Table 1: Structure, biological activity data and calculated log values of the compounds considered for QSAR 
Sl. No.  Compounds Structure  IC50 (ug/ml)  Log IC50 References 
1. CID_2764_Ciprofloxacin  T 
 
0.5 -0.301  12 
2. CID_4583_Ofloxacin 
 
0.75 -0.124  12 
3. CID_149096_Levofloxacin  T 
 











6. CID_5379_Gatifloxacin  T 
 
0.12 -0.920  13 
7. CID_62959_Trovafloxacin 
 
32 1.505  13 
8 CID_72474_Grepafloxacin. 
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9. CID_461399_Satifloxacin  T 
 
0.1 0  13 
10. CID_124093_Garenoxacin 
 
1.0 0  13 
11. CID_121960_WIN57273 
 
1.0 0  13 
12. CID_121833_CI-934 
 
2.0 0.301  13 
13. CID_487101_WQ-3034 
 
0.78 -0.107  13 
14. CID_477670_Olamufloxacin  T 
 
0.78 -0.107  13 
15. CID_189912_Cadrofloxacin 
 
0.25 -0.602  13 
16. CID_65958_Balofloxacin  T 
 
2.0 0.301  13 
17. CID_60063_Clinafloxacin 
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0.78 -0.107  13 
19. CID_00119375_BAYy3118 
 
0.06 -1.221  13 
T= Test set 
 
Table 2: Uni-column Statistics for training and test sets 
Set  Average Max  Min  StdDev Sum 
Training -0.1273  1.5050 -1.2210 0.6262  -1.6550 
Test -0.2213  0.3010  -0.9200  0.4088  -1.3280 
 
Table 3: Experimental and predicted activity of the compounds 
Sl. No.  Compounds  Exp Log IC50 Pred_MR Pred_PLSR Pred_PCR  Pred_kNN-MFA 
1. CID_2764_Ciprofloxacin  T -0.301  -0.130536  -0.118652  -0.118652  0.091470 
2. CID_4583_Ofloxacin  -0.124  -0.096736 -0.068184  -0.068184  -0.080296 
3. CID_149096_Levofloxacin  T -0.301  -0.164698  -0.141946 -0.141946  -0.225776 
4. CID_60464_Sparfloxacin -0.698 -0.662853  -0.693905  -0.693905  -0.741774 
5. CID_152946_Moxifloxacin  -0.301 -0.166971  -0.155746  -0.155746  -0.396863 
6. CID_5379_Gatifloxacin  T -0.920  -0.788032  -0.790338  -0.790338  -0.697438 
7. CID_62959_Trovafloxacin 1.505  1.441020  1.420574  1.420574  1.475813 
8. CID_72474_Grepafloxacin  0  -0.194400 -0.181942  -0.181942  -0.003357 
9. CID_461399_Satifloxacin  T 0  -1.076203  -1.071753  -1.071753  -0.804463 
10. CID_124093_Garenoxacin 0  -0.182312 -0.179561  -0.179561  -0.096659 
11. CID_121960_WIN57273  0  0.226791 0.208722  0.208722  0.158183 
12. CID_121833_CI-934  0.301  0.140702 0.148581  0.148581  0.072382 
13. CID_487101_WQ-3034  -0.107 0.113440  0.136374  0.136374  0.079528 
14. CID_477670_Olamufloxacin  T -0.107  -0.312990 -0.287095  -0.287095  -0.362230 
15. CID_189912_Cadrofloxacin  -0.602 -0.540839  -0.550700  -0.550700  -0.584534 
16. CID_65958_Balofloxacin  T 0.301  -0.785967  -0.788517  -0.788517  -0.969202 
17. CID_60063_Clinafloxacin -0.301 -0.294585  -0.280946  -0.280946  -0.231961 
18. CID_65947_Prulifloxacin  -0.107 -0.189217  -0.201832  -0.201832  -0.110201 
19. CID_00119375_BAYy3118 -1.221  -1.249021 -1.256416  -1.256416  -1.195300 
T= Test set; Pred_MR, Pred_PLSR, Pred_PCR, Pred_kNN-MFA: Predicted activity of each model 
 
 